Immunohistological analysis of thymoma by molecules differentially expressed in the thymic cortex and medulla, and its application in the differential diagnosis of thymoma from esophageal and lung cancer.
The purpose of this study was to verify the WHO classification of thymic tumors using immunohistological methods, and to discover whether these methods can be applied to differentiate thymoma from squamous cell carcinoma (SCC) of the esophagus and the lung. Twenty-nine thymoma cases were classified according to WHO and were then immunohistologically examined for the positivity of these molecules. All thymoma cases investigated in this study were positive for IL-1R, and most of them were also positive for bek. In contrast, UH-1 was highly positive in B1 and B2 type thymomas, but negative or weakly positive in A, AB and B3 type thymomas. Twelve esophageal cancers and 21 lung cancers were also examined for the positivity of the same molecules. All esophageal cancers were negative for UH-1. Three of 12 cases were weakly positive for IL-1R, and four of these 12 cases were also weakly positive for bek. Twelve of 21 lung cancer cases were adenocarcinomas, all of them negative for IL-1R, bek and UH-1. Nine of 21 lung cancer cases were SCCs, all of them negative for UH-1. Eight of nine SCC cases were strongly positive for IL-1R, while seven of these were weakly positive for bek. We conclude that the WHO classification of thymic tumors is still valid as demonstrated by immunohistological analysis and that the positivity of UH-1, IL- 1R and bek might be helpful in differentiating thymoma from SCC of the esophagus and the lung.
Shiraishi
J
J
Department of Pathology and Immunology, Tokyo Medical and Dental University Graduate School, Japan.
Utsuyama
M
M
Akashi
T
T
Nemoto
T
T
Ohashi
K
K
Akamatsu
H
H
Sunamori
M
M
Kitagawa
M
M
Hirokawa
K
K
D000230:Adenocarcinoma / Q000737:chemistry / Q000378:metabolism / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000276:immunology; D000951:Antigens, Neoplasm / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis / Q000378:metabolism*; D002294:Carcinoma, Squamous Cell / Q000737:chemistry / Q000378:metabolism / Q000473:pathology; D002675:Child, Preschool; D003937:Diagnosis, Differential; D004938:Esophageal Neoplasms / Q000737:chemistry / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007223:Infant; D008175:Lung Neoplasms / Q000737:chemistry / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D020794:Receptor Protein-Tyrosine Kinases / Q000032:analysis; D051497:Receptor, Fibroblast Growth Factor, Type 2; D017468:Receptors, Fibroblast Growth Factor / Q000032:analysis; D017472:Receptors, Interleukin-1 / Q000032:analysis; D013945:Thymoma / Q000737:chemistry / Q000145:classification / Q000378:metabolism* / Q000473:pathology; D013950:Thymus Gland / Q000196:embryology / Q000378:metabolism* / Q000473:pathology; D013953:Thymus Neoplasms / Q000737:chemistry / Q000145:classification / Q000378:metabolism* / Q000473:pathology
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D017468:Receptors, Fibroblast Growth Factor; D017472:Receptors, Interleukin-1; C496353:FGFR2 protein, human; D020794:Receptor Protein-Tyrosine Kinases; D051497:Receptor, Fibroblast Growth Factor, Type 2